Phase 4 post-marketing study evaluating GLP-1 drug safety and tolerability over 24 weeks provides important long-term real-world safety data beyond pivotal trials.
Key findingPhase 4 post-marketing study evaluating GLP-1 drug safety and tolerability over 24 weeks provides im
What the researchers found
Phase 4 post-marketing study evaluating GLP-1 drug safety and tolerability over 24 weeks provides important long-term real-world safety data beyond pivotal trials.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Participants had 4-14 migraine days per month. Treatment: rimegepant 75 mg once daily for 24 weeks.
How the study worked
In publication.
Who was studied
Adults with episodic migraine (4-14 migraine days per month)
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
A phase 4, 24-week, open-label study to evaluate the safety and tolerability of once-daily dosing of 75 mg rimegepant for episodic migraine prevention.
The journal of headache and pain, 27(1), 17
Citation
Antinew, Jeremias; Fountaine, Robert J; Loprinzo, Vittorio; Straghan, Esther; Dubrovin, Sergey; DeBesi, Patrizia; Vatakis, Nick; Fullerton, Terence. (2025). A phase 4, 24-week, open-label study to evaluate the safety and tolerability of once-daily dosing of 75 mg rimegepant for episodic migraine prevention.. The journal of headache and pain, 27(1), 17. https://doi.org/10.1186/s10194-025-02225-7